Last reviewed · How we verify
Nitisinone, capsule
At a glance
| Generic name | Nitisinone, capsule |
|---|---|
| Sponsor | Swedish Orphan Biovitrum |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Bioequivalence of Orfadin 20 mg Compared to Orfadin 10 mg Capsules. (PHASE1)
- A Study to Investigate the Potential Influence of Nitisinone on the Metabolism and the Transport of Other Drugs in Healthy Volunteers (PHASE1)
- Bioequivalence Study of Two Oral Nitisinone Formulations to Treat Hereditary Tyrosinemia (HT-1) (PHASE1)
- Bioequivalence Study of Two Nitisinone Formulations Compared to Orfadin (PHASE1)
- Bioequivalence of Orfadin Suspension Compared to Orfadin Capsules, and the Effect of Food on the Bioavailability of the Suspension (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Nitisinone, capsule CI brief — competitive landscape report
- Nitisinone, capsule updates RSS · CI watch RSS
- Swedish Orphan Biovitrum portfolio CI